Artivion, Inc. (AORT)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Artivion, Inc. currently loses $11.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Artivion beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 6 based on preliminary results, as adjusted EPS of $0.13 topped the $0.00 estimate by about +5100% and revenue of about $125.8 million came in roughly 5% above the $120.0 million consensus. Revenue rose 11.3% from about $113.0 million a year ago, while gross profit reached about $80.5 million and gross margin held near 64%. Adjusted EPS was down 45.8% from $0.24 in the prior-year quarter. Operating cash flow was negative $112,000. For the next period, consensus calls for EPS of $0.13 on revenue of $121.5 million.
About Artivion, Inc.
Artivion, Inc. develops and sells implantable and preservation products for cardiac and vascular surgery as a healthcare company listed on the NYSE under AORT. Formerly CryoLife, the company generates $441.3 million of revenue in FY2025 from a portfolio centered on aortic repair, surgical sealants, tissue patches, valves, and preservation services.
Today's Snapshot
AORT closed slightly higher at 25.22.
Trading Volume
Above 10d avg 544.0K
553.7K
vs S&P 500 Today
Outperforming Market
+0.84%
Updated: September 10, 2026 at 12:04 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$26.11 - $33.12Sell
- RSI (14)39.72Neutral
- Stochastic %K (14, 3, 3)7.85Buy
- MACD Level (12, 26)-0.28Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.